1. Home
  2. IFF vs BIIB Comparison

IFF vs BIIB Comparison

Compare IFF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFF
  • BIIB
  • Stock Information
  • Founded
  • IFF 1833
  • BIIB 1978
  • Country
  • IFF United States
  • BIIB United States
  • Employees
  • IFF N/A
  • BIIB N/A
  • Industry
  • IFF Major Chemicals
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IFF Industrials
  • BIIB Health Care
  • Exchange
  • IFF Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • IFF 19.6B
  • BIIB 24.2B
  • IPO Year
  • IFF N/A
  • BIIB 1991
  • Fundamental
  • Price
  • IFF $65.85
  • BIIB $168.52
  • Analyst Decision
  • IFF Strong Buy
  • BIIB Buy
  • Analyst Count
  • IFF 15
  • BIIB 24
  • Target Price
  • IFF $85.15
  • BIIB $174.62
  • AVG Volume (30 Days)
  • IFF 2.5M
  • BIIB 1.8M
  • Earning Date
  • IFF 11-04-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • IFF 2.43%
  • BIIB N/A
  • EPS Growth
  • IFF N/A
  • BIIB N/A
  • EPS
  • IFF N/A
  • BIIB 10.97
  • Revenue
  • IFF $11,072,000,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • IFF N/A
  • BIIB $2.97
  • Revenue Next Year
  • IFF N/A
  • BIIB N/A
  • P/E Ratio
  • IFF N/A
  • BIIB $15.27
  • Revenue Growth
  • IFF N/A
  • BIIB 4.77
  • 52 Week Low
  • IFF $59.14
  • BIIB $110.04
  • 52 Week High
  • IFF $91.65
  • BIIB $175.86
  • Technical
  • Relative Strength Index (RSI)
  • IFF 57.80
  • BIIB 74.64
  • Support Level
  • IFF $65.04
  • BIIB $151.83
  • Resistance Level
  • IFF $67.75
  • BIIB $157.79
  • Average True Range (ATR)
  • IFF 1.69
  • BIIB 5.59
  • MACD
  • IFF 0.36
  • BIIB 1.37
  • Stochastic Oscillator
  • IFF 71.50
  • BIIB 95.37

About IFF International Flavors & Fragrances Inc.

International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrances producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: